FORBIMED

RESEARCH COLLABORATION - BIOMARKERS IN THE FIGHT AGAINST INFECTIOUS DISEASES

Logo FORBIMED

I3 - Development of Immunological Assays for Immunomonitoring in the Context of a Viral Vaccination Platform

The company AmVac Research GmbH provides a vector platform
based on a replication deficient viral vector. For the preclinical and clinical development of vector based vaccines it is essential to establish biomarkers that reflect the vaccine induced  immune response qualitatively and quantitatively and therefore allow to draw conclusions on the provided protective effects. Such bioassays for the B and T cellular immune response will be developed in this project.

Project partners:

Information

Launching date

10.2013

End

01.2017

Funded by

Bayerische Forschungsstiftung